je.st
news
Will hepatitis C drug continue blockbuster sales?
2014-07-24 00:20:32| Biotech - Topix.net
Gilead Sciences' $1,000-a-day hepatitis C pill is facing a firestorm of criticism from insurers and lawmakers, but none of those obstacles are likely to stop the Foster City company from reporting blockbuster revenues during the second quarter today.
Tags: sales
continue
drug
hepatitis
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||